{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:03:36Z","timestamp":1788246216413,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007787","name":"National Research Centre","doi-asserted-by":"publisher","award":["12010108"],"award-info":[{"award-number":["12010108"]}],"id":[{"id":"10.13039\/100007787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bioorg.2021.105424","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T16:57:25Z","timestamp":1634576245000},"page":"105424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives"],"prefix":"10.1016","volume":"117","author":[{"given":"Mohammed S.","family":"Abdel-Maksoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Mohamed Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Abdel-Sattar El-Azzouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nabil Aboul-Enein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hyun","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105424_b0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejps.2018.08.030","article-title":"Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects","volume":"124","author":"Trivedi","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2021.105424_b0010","doi-asserted-by":"crossref","first-page":"105045","DOI":"10.1016\/j.ejps.2019.105045","article-title":"Design, synthesis and anticancer evaluation of novel 1,3-benzodioxoles and1,4-benzodioxines","volume":"139","author":"Hassan","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2021.105424_b0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2021.105424_b0020","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejps.2016.03.022","article-title":"Novel fluorinated docetaxel analog for anti-hepatoma: Molecular docking and biological evaluation","volume":"88","author":"Hao","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105424_b0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0006-2952(00)00412-3","article-title":"Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6","volume":"60","author":"Vanden Berghe","year":"2000","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105424_b0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/1568026054985902","article-title":"The biology of p38 kinase: a central role in inflammation","volume":"5","author":"Schieven","year":"2005","journal-title":"Curr. Top. Med. Chem."},{"issue":"7-8","key":"10.1016\/j.bioorg.2021.105424_b0035","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.intimp.2005.03.005","article-title":"Chemokine production and E-selectin expression in activated endothelial cells are inhibited by p38 MAPK (mitogen activated protein kinase) inhibitor RWJ 67657","volume":"5","author":"Westra","year":"2005","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105424_b0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.febslet.2004.12.066","article-title":"Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE\/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways","volume":"579","author":"Takami","year":"2005","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105424_b0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell."},{"key":"10.1016\/j.bioorg.2021.105424_b0050","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ejmech.2017.08.044","article-title":"Recent advances in the discovery of small molecule c-Met Kinase inhibitors","volume":"143","author":"Palak","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105424_b0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105424_b0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc1360","article-title":"The discovery of receptor tyrosine kinases: targets for cancer therapy","volume":"4","author":"Gschwind","year":"2004","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105424_b0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ddr.21678","article-title":"Structural and biological survey of 7-chloro-4-(piperazin-1-yl)quinoline and its derivatives","volume":"81","author":"El-Azzouny","year":"2020","journal-title":"Drug Dev Res."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105424_b0070","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105424_b0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003495-200969020-00006","article-title":"Sorafenib: a review of its use in advanced hepatocellular carcinoma","volume":"69","author":"Keating","year":"2009","journal-title":"Drugs."},{"issue":"22","key":"10.1016\/j.bioorg.2021.105424_b0080","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"Oncogene."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105424_b0085","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.bmc.2019.03.062","article-title":"Anticancer profile of newly synthesized BRAF inhibitors possess 5(pyrimidin-4-yl)imidazo[2,1-b]thiazolescaffold","volume":"27","author":"Abdel-Maksoud","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105424_b0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"15","key":"10.1016\/j.bioorg.2021.105424_b0095","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1016\/j.bmc.2017.05.044","article-title":"Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity","volume":"25","author":"Qu","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejmech.2017.04.037","article-title":"Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia","volume":"135","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105424_b0105","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2013.794220","article-title":"Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies","volume":"9","author":"Gibney","year":"2013","journal-title":"Expert. Opin. on Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105424_b0110","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejmech.2007.03.030","article-title":"Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents","volume":"43","author":"Bekhit","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0115","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/epj.epj_64_19","article-title":"Green synthesis and biological screening of some fluorinated pyrazole chalcones in search of potent anti-inflammatory and analgesic agents","volume":"19","author":"Jadhav","year":"2020","journal-title":"Egypt Pharmaceut. J."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105424_b0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14756366.2018.1530225","article-title":"Design, synthesis, in vitro anticancer evaluation, kinase inhibitory effects, and pharmacokinetic profile of new 1,3,4-triarylpyrazole derivatives possessing terminal sulfonamide moiety","volume":"34","author":"Abdel-Maksoud","year":"2019","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2021.105424_b0125","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a Potent and selective dual inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0130","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis","volume":"18","author":"John","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105424_b0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Reinhard","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2021.105424_b0140","doi-asserted-by":"crossref","unstructured":"El-Gamal, M.I., Abdel-Maksoud, M.S., Gamal El-Din, M.M., Shin, J.S., Lee, K.T., Yoo, K. H., Oh, C.H. Synthesis, in vitro antiproliferative and antiinflammatory activities, and kinase inhibitory effects of new 1,3,4-triarylpyrazole derivatives. Anticancer Agents Med. Chem. 17(4), 2017, 75-84. https:\/\/doi.org\/10.2174\/1871520616666160620074534.","DOI":"10.2174\/1871520616666160620074534"},{"issue":"10","key":"10.1016\/j.bioorg.2021.105424_b0145","doi-asserted-by":"crossref","first-page":"6877","DOI":"10.1021\/acs.jmedchem.1c00230","article-title":"Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity","volume":"64","author":"Abdel-Maksoud","year":"2021","journal-title":"J. Med.Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejmech.2017.01.006","article-title":"Design and synthesis of new RAF kinase-inhibiting antiproliferative quinoline derivatives. Part 2: Diarylurea derivatives","volume":"127","author":"El-Gamal","year":"2017","journal-title":"Eur. J. Med. Chem"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105424_b0155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00044-016-1529-7","article-title":"Broad-spectrum antiproliferative activity of a series of 6-(4-fluorophenyl)-5-(2-substituted pyrimidin-4-yl)imidazo[2,1-b]thiazole derivatives","volume":"25","author":"Abdel-Maksoud","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2021.105424_b0160","doi-asserted-by":"crossref","first-page":"103349","DOI":"10.1016\/j.bioorg.2019.103349","article-title":"Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors","volume":"93","author":"Abdel-Maksoud","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0165","doi-asserted-by":"crossref","first-page":"113277","DOI":"10.1016\/j.ejmech.2021.113277","article-title":"Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E\/p38\u03b1 inhibitors","volume":"215","author":"Ali","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0170","doi-asserted-by":"crossref","first-page":"103473","DOI":"10.1016\/j.bioorg.2019.103473","article-title":"Design and synthesis of novel parabanic acid derivatives as anticonvulsants","volume":"94","author":"Aboutabl","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2021.105424_b0175","doi-asserted-by":"crossref","first-page":"115493","DOI":"10.1016\/j.bmc.2020.115493","article-title":"Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF","volume":"28","author":"Abdel-Maksoud","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105424_b0180","unstructured":"https:\/\/cancerstatisticscenter.cancer."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105424_b0185","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bioorg.2021.105424_b0190","unstructured":"https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html."},{"key":"10.1016\/j.bioorg.2021.105424_b0195","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"10.1016\/j.bioorg.2021.105424_b0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejmech.2014.06.027","article-title":"Synthesis and antitumor activity of pyrido [2,3-d]pyrimidine and pyrido[2,3-d] [1,2,4] triazolo[4,3-a]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest","volume":"83","author":"Fares","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105424_b0205","article-title":"Inhibition of lipopolysaccharide-induced nitric oxide and prostaglandin E2 production by chloroform fraction of Cudrania tricuspidata in RAW 264.7 macrophages. BMC Complement","volume":"12","author":"Yang","year":"2012","journal-title":"Altern. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105424_b0210","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and Inflammation","volume":"31","author":"Emanuela","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105424_b0215","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.3390\/molecules17055095","article-title":"Synthesis, Molecular Properties Prediction, and Anti-staphylococcal Activity of N-Acylhydrazones and New 1,3,4-Oxadiazole Derivatives","volume":"17","author":"de Oliveira","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2021.105424_b0220","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41598-018-36089-6","article-title":"Bioactive glycoalkaloides isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells","volume":"9","author":"Fekry","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.bioorg.2021.105424_b0225","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3390\/molecules23102556","article-title":"Synthesis of New Triarylpyrazole Derivatives Possessing Terminal Sulfonamide Moiety and Their Inhibitory Effects on PGE2 and Nitric Oxide Productions in Lipopolysaccharide-Induced RAW 264.7 Macrophages","volume":"23","author":"Abdel-Maksoud","year":"2018","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.bioorg.2021.105424_b0230","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/cells8101163","article-title":"Anti-Inflammatory mechanisms of Koreanaside A, a lignan isolated from the flower of Forsythia koreana, against LPS-induced macrophage activation and DSS-induced colitis mice: the crucial role of AP-1, NF-\u03baB, and JAK\/STAT signaling","volume":"8","author":"Kim","year":"2019","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105424_b0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jrr\/rrab005","article-title":"A novel radiolytic rotenone derivative, rotenoisin A, displays potent anticarcinogenic activity in breast cancer cells","volume":"62","author":"Bak","year":"2021","journal-title":"Journal of Radiation Research"},{"key":"10.1016\/j.bioorg.2021.105424_b0240","unstructured":"http:\/\/www.rcsb.org\/."},{"issue":"6","key":"10.1016\/j.bioorg.2021.105424_b0245","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1007\/s11164-013-1488-2","article-title":"Design and synthesis of certain substituted cycloalkanecarboxamides structurally related to safinamide with anticonvulsant potential","volume":"41","author":"Aboul-Enein","year":"2015","journal-title":"Res. Chem. Intermed."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821008014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:55:43Z","timestamp":1777463743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821008014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"alternative-id":["S0045206821008014"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105424","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105424"}}